ArticleMalaria journal2025
Measuring growth, resistance, and recovery after artemisinin treatment of Plasmodium falciparum in a single semi-high-throughput assay.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potent acridone antimalarial against all three life stages of Plasmodium.Nature communications · 2026Article
- Functional validation of thebioRxiv : the preprint server for biology · 2026Article
- Optimization of Prodiginines as Single-Dose Curative Antimalarials.Journal of medicinal chemistry · 2025Article
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
backgroundArtemisinin partial resistance (ART-R) has spread throughout Southeast Asia and mutations in Pfkelch13, the molecular marker of resistance, are widely reported in East Africa. Effective in vitro assays and robust phenotypes are crucial for monitoring populations for the emergence and spread of resistance. The recently developed extended Recovery Ring-stage Survival Assay used a qPCR-based readout to reduce the labour intensiveness for in vitro phenotyping of ART-R and improved correlation with the clinical phenotype of ART-R. Here, the assay is extended and refined to include measurements of parasite growth and recovery after drug exposure. Clinical isolates and progeny from two genetic crosses were used to optimize and validate the reliability of a straight-from-blood, SYBR Green-based qPCR protocol in a 96-well plate format to accurately measure phenotypes with this new Growth, Resistance, and Recovery assay (GRRA).
resultsThe assay determined growth between 6 and 96 h, resistance at 120 h, and recovery from 120 to 192 h. Growth can be accurately captured by qPCR and is shown by reproduction of previous growth phenotypes from HB3 × Dd2. Resistance measured at 120 h continually shows the most consistent phenotype for ring stage susceptibility. Recovery identifies an additional response to drug in parasites that are determined sensitive by replicative viability at 120 h. Comparison of progeny phenotypes for Growth versus Resistance showed a minor but significant correlation, whereas Growth versus Recovery and Resistance versus Recovery showed no significant correlation. Additionally, dried blood spot (DBS) samples matched replicative viability measured from liquid samples demonstrating Resistance can be easily quantified using either storage method.
conclusionsThe direct-from-blood qPCR-based methodology provides the throughput needed to quickly measure large numbers of parasites for multiple relevant phenotypes. Growth can reveal fitness defects and illuminate relationships between proliferation rates and drug response. Recovery serves as a complementary phenotype to resistance that quantifies the ability of sensitive parasites to tolerate drug exposure. All three phenotypes offer a comprehensive assessment of parasite-drug interaction each with potential independent genetic determinants of main effect and overlapping secondary effects. By adapting the method to include DBS, readouts can be easily extended to ex vivo surveillance applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.